Insulet Corporation

- No mention of any current or planned new fundraising through debt or equity in the provided pages. - The company expects 2026 net interest expense to be approximately $40 million, up about $15 million primarily due to lower interest income, implying use of existing debt. - Focus is on growing revenue and operating margin expansion to support earnings and free cash flow. - Capital expenditures are ramping up to support global manufacturing expansion but are funded through operations. - No explicit indication of issuing new debt or equity to raise capital during this period.

- The company is ramping up capital expenditures to support continued global manufacturing expansion plans. - A water-type manufacturing building is expected to be ready by year-end and go live in 2029. - Investments in R&D are being increased to support the innovation roadmap and key clinical development programs, including Omnipod 6 and fully closed loop for type 2 diabetes. - The ramp-up in sales and marketing investments is planned to expand the sales force and prepare for upcoming product launches such as Libre 3 Plus integration and algorithm enhancements. - These strategic investments aim to enable continued growth, broaden healthcare professional coverage, increase new customer starts, and support global scale.

- Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24%. - U.S. Omnipod revenue expected to grow 20%-22% in 2026, driven by new customer starts, positive pricing, and sustained utilization. - International Omnipod revenue forecast at 26%-28% growth in 2026, supported by new customer sites, price/mix benefits from DASH to Omnipod 5 transition, and geographic expansion (e.g., Spain launch H2 2026). - 2027 growth to be supported by the launch of Omnipod 6 and full benefit of salesforce expansion. - Algorithm improvements and Libre 3 Plus sensor integration expected to expand total addressable market (e.g., ~450,000 additional users in U.S.). - Continued commercial investments, salesforce upskilling, prescriber education, and market access initiatives aimed at sustaining high growth rates and category expansion. - Long-term confidence in sustaining approximately 20% growth driven by innovation and commercial catalysts.

- Adjusted EPS expected to increase by more than 25% in 2026. - Operating margin anticipated to expand by approximately 100 basis points in 2026, driven by strong top-line growth, gross margin expansion, and disciplined spending. - First quarter 2026 adjusted operating margin expanded 110 basis points to 17.5%. - Free cash flow expected to be approximately flat to 2025 levels, supported by growth and margin expansion, partially offset by increased capital expenditures. - Continued investments planned in R&D and sales & marketing to support innovation and commercial expansion. - Confidence in sustaining 20% total Omnipod revenue growth over long-run plan, driven by product innovations (Omnipod 6, Libre 3 Plus integration, algorithm enhancements) and sales force expansion. - Foreign currency expected to provide a favorable impact (~100 basis points) on full-year revenue growth in 2026.

The provided document does not explicitly mention the current or expected orderbook or pending orders for Insulet or its Omnipod products. However, insights related to demand and growth include: - Strong momentum in new customer starts, with full-year growth expected despite some quarter-to-quarter variability. - Continued sequential quarterly growth in new customer starts (NCS). - International Omnipod 5 available in 19 countries with plans to expand into Spain in H2 2026. - Launch of Omnipod 6 in 2027 expected to drive share gains and customer starts. - Expansion of sales force and commercial initiatives aimed at increasing customer adoption. - Integration with Libre 3 Plus sensor opens access to additional 450,000 users. - No direct quantitative orderbook or pending order figures disclosed.